Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Due to an inability to cross the blood brain barrier, certain drugs need to be directly delivered into the central nervous system (CNS). Our lab focuses specifically on antisense oligonucleotides (ASOs), though the techniques shown in the video here can also be used to deliver a plethora of other drugs to the CNS. Antisense oligonucleotides (ASOs) have the capability to knockdown sequence-specific targets (1) as well as shift isoform ratios of specific genes (2). To achieve widespread gene knockdown or splicing in the CNS of mice, the ASOs can be delivered into the brain using two separate routes of administration, both of which we demonstrate in the video. The first uses Alzet osmotic pumps, connected to a catheter that is surgically implanted into the lateral ventricle. This allows the ASOs to be continuously infused into the CNS for a designated period of time. The second involves a single bolus injection of a high concentration of ASO into the right lateral ventricle. Both methods use the mouse cerebral ventricular system to deliver the ASO to the entire brain and spinal cord, though depending on the needs of the study, one method may be preferred over the other.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454
Toxic Proteins in Neurodegenerative Disease
Taylor, J. P., Hardy, J., & Fischbeck, K. H. (2002) · Science · doi:10.1126/science.1067122 · Cited by 1,251
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Astrocytes from familial and sporadic ALS patients are toxic to motor neurons
Haidet-Phillips, A. M., Hester, M. E., Miranda, C. J., Meyer, K., Braun, L., Frakes, A., Song, S., Likhite, S., Murtha, M. J., Foust, K. D., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1957 · Cited by 782
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
Antisense oligonucleotide therapy for neurodegenerative disease
Smith, R. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25424 · Cited by 506
Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents
Vickers, T. A., Koo, S., Bennett, C. F., Crooke, S. T., Dean, N. M., & Baker, B. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210326200 · Cited by 461
Cited by
Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies
Sanders, D. W., Kaufman, S. K., DeVos, S. L., Sharma, A. M., Mirbaha, H., Li, A., Barker, S. J., Foley, A. C., Thorpe, J. R., Serpell, L. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.04.047 · Cited by 986
Self-citationBrain regulatory T cells suppress astrogliosis and potentiate neurological recovery
Ito, M., Komai, K., Mise-Omata, S., Iizuka-Koga, M., Noguchi, Y., Kondo, T., Sakai, R., Matsuo, K., Nakayama, T., Yoshie, O., et al. (2019) · Nature · doi:10.1038/s41586-018-0824-5 · Cited by 784
DeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Kebodeaux, C. S., Wegener, A. J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0481 · Cited by 516
“Surgical placement of ICV pumps and tissue collection Aspreviously described (16, 61),micewere anesthetizedwith isoflurane, and 28-day Alzet osmotic pumps with ASO were implanted in a subcutaneous pocket formed on the back of the mice.”
MethodSelf-citationStancu, I.-C., Cremers, N., Vanrusselt, H., Couturier, J., Vanoosthuyse, A., Kessels, S., Lodder, C., Brône, B., Huaux, F., Octave, J.-N., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-01957-y · Cited by 447
Impaired Amino Acid Transport at the Blood Brain Barrier Is a Cause of Autism Spectrum Disorder
Tărlungeanu, D. C., Deliu, E., Dotter, C. P., Kara, M., Janiesch, P. C., Scalise, M., Galluccio, M., Tesulov, M., Morelli, E., Sonmez, F. M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.013 · Cited by 367
Astrocytic interleukin-3 programs microglia and limits Alzheimer’s disease
McAlpine, C. S., Park, J., Griciuc, A., Kim, E., Choi, S. H., Iwamoto, Y., Kiss, M. G., Christie, K. A., Vinegoni, C., Poller, W. C., et al. (2021) · Nature · doi:10.1038/s41586-021-03734-6 · Cited by 322
Antisense Reduction of Tau in Adult Mice Protects against Seizures
DeVos, S. L., Goncharoff, D. K., Chen, G., Kebodeaux, C. S., Yamada, K., Stewart, F. R., Schuler, D. R., Maloney, S. E., Wozniak, D. F., Rigo, F., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2107-13.2013 · Cited by 311
“As described previously (Smith et al., 2006; DeVos and Miller, 2013a), mice were anesthetized with isoflurane and 28 d osmotic intracerebroventricular (ICV) pumps (ALZET) with ASO were implanted in a subcutaneous pocket that was formed on the back of the mouse.”
BackgroundMethodInfluentialSelf-citationMethod for widespread microRNA-155 inhibition prolongs survival in ALS-model mice
Koval, E. D., Shaner, C., Zhang, P., du Maine, X., Fischer, K., Tay, J., Chau, B. N., Wu, G. F., & Miller, T. M. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt261 · Cited by 236
“For implantation, mice were anesthetized in a chamber with 5% isoflurane/oxygen mixture and confirmed to be unconscious before being placed in Kopf Model 940 small animal stereotaxic apparatus, fitted with ear bars (29).”
Self-citationRoy, E. R., Chiu, G., Li, S., Propson, N. E., Kanchi, R., Wang, B., Coarfa, C., Zheng, H., & Cao, W. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.018 · Cited by 236
Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis
Huynh, T.-P. V., Liao, F., Francis, C. M., Robinson, G. O., Serrano, J. R., Jiang, H., Roh, J., Finn, M. B., Sullivan, P. M., Esparza, T. J., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.11.014 · Cited by 209
“Bolus injections of ASO into adult mice were performed as previously described (DeVos and Miller, 2013b).”
MethodIntrathecal drug delivery in the era of nanomedicine
Fowler, M. J., Cotter, J. D., Knight, B. E., Sevick-Muraca, E. M., Sandberg, D. I., & Sirianni, R. W. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.02.006 · Cited by 187
“Advantages of ICV administration compared to other routes include the relative consistency of the surgical procedure and well-understood approaches for cannulation.[63] Disadvantages include damage produced by passing the needle through healthy brain, the potential for backflow, asymmetry when only one ventricle is in…”
BackgroundNoncoding RNAs in neurodegeneration
Salta, E., & De Strooper, B. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.90 · Cited by 183
Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model
Schoch, K. M., DeVos, S. L., Miller, R. L., Chun, S. J., Norrbom, M., Wozniak, D. F., Dawson, H. N., Bennett, C. F., Rigo, F., & Miller, T. M. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.042 · Cited by 175
Self-citationSuppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide
Tran, H., Moazami, M. P., Yang, H., McKenna-Yasek, D., Douthwright, C. L., Pinto, C., Metterville, J., Shin, M., Sanil, N., Dooley, C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01557-6 · Cited by 174
Antisense oligonucleotides: treating neurodegeneration at the level of RNA
DeVos, S. L., & Miller, T. M. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0194-5 · Cited by 164
“- Measure a range of ASO doses using Alzet osmotic pumps or intraventricular bolus injection to determine a working range of ASO [62] - Collect hippocampus around injection site, extract mRNA, and analyze for desired effect - NOTE: While 8−10 ASOs is a good starting point, it may take up to 80 ASOs in cell culture per…”
MethodSelf-citationBarker, S. J., Thayer, M. B., Kim, C., Tatarakis, D., Simon, M. J., Dial, R., Nilewski, L., Wells, R. C., Zhou, Y., Afetian, M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adi2245 · Cited by 142
Self-citationPrakash, P., Manchanda, P., Paouri, E., Bisht, K., Sharma, K., Rajpoot, J., Wendt, V., Hossain, A., Wijewardhane, P. R., Randolph, C. E., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.04.029 · Cited by 152
Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues
Naseri Kouzehgarani, G., Feldsien, T., Engelhard, H. H., Mirakhur, K. K., Phipps, C., Nimmrich, V., Clausznitzer, D., & Lefebvre, D. R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.002 · Cited by 95
Lima da Cruz, R. V., Moulin, T. C., Petiz, L. L., & Leão, R. N. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00312 · Cited by 84
Acute Trem2 reduction triggers increased microglial phagocytosis, slowing amyloid deposition in mice
Schoch, K. M., Ezerskiy, L. A., Morhaus, M. M., Bannon, R. N., Sauerbeck, A. D., Shabsovich, M., Jafar-nejad, P., Rigo, F., & Miller, T. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2100356118 · Cited by 78
Self-citationProtein and mRNA Delivery Enabled by Cholesteryl‐Based Biodegradable Lipidoid Nanoparticles
Li, Y., Jarvis, R., Zhu, K., Glass, Z., Ogurlu, R., Gao, P., Li, P., Chen, J., Yu, Y., Yang, Y., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004994 · Cited by 75
Hu, P., Liu, J., Maita, I., Kwok, C., Gu, E., Gergues, M. M., Kelada, F., Phan, M., Zhou, J.-N., Swaab, D. F., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.2410-19.2020 · Cited by 71
“…was injected into the lateral ventricle of mice (anteroposterior (cid:6) 0.5 mm; mediolateral (cid:8) 1.0– 1.1 mm; dorsoventral (cid:6) 2.5 mm) (DeVos and Miller, 2013) through an injectioncannula(connectedtoasyringewithUltraMicroPump,UMP3;…”
BackgroundInfluentialBennett, R. E., & Brody, D. L. (2014) · Journal of Neurotrauma · doi:10.1089/neu.2013.3320 · Cited by 64
Motor neuron-derived microRNAs cause astrocyte dysfunction in amyotrophic lateral sclerosis
Hoye, M. L., Regan, M. R., Jensen, L. A., Lake, A. M., Reddy, L. V., Vidensky, S., Richard, J.-P., Maragakis, N. J., Rothstein, J. D., Dougherty, J. D., et al. (2018) · Brain · doi:10.1093/brain/awy182 · Cited by 63
Self-citationHu, P., Maita, I., Phan, M. L., Gu, E., Kwok, C., Dieterich, A., Gergues, M. M., Yohn, C. N., Wang, Y., Zhou, J.-N., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01070-3 · Cited by 49
Djebari, S., Iborra-Lázaro, G., Temprano-Carazo, S., Sánchez-Rodríguez, I., Nava-Mesa, M. O., Múnera, A., Gruart, A., Delgado-García, J. M., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.2849-20.2021 · Cited by 48
“Drugs included in this study were administered by intracerebroventricular (i.c.v.) injections that would affect the dorsal hippocampus, among other regions in the brain (DeVos and Miller, 2013; Sánchez-Rodríguez et al., 2020).”
Metadata
- Authors
- DeVos, S. L., & Miller, T. M.
- Venue
- Journal of Visualized Experiments
- Publisher
- MyJove Corporation
- Published
- 2013-05-12
- Issue
- 75
- Pages
- e50326-e50326
- ISSN
- 1940-087X (ISSN-L)
- OpenAlex
- W2108150032
- Cited by
- 165
- References
- 8
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.